Treatment for Adenocarcinoma of Lung

Phase-Based Estimates
1
Effectiveness
1
Safety
Mayo Clinic in Rochester, Rochester, MN
+3 More
Eligibility
18+
All Sexes
Eligible conditions
Adenocarcinoma of Lung

Study Summary

This study is evaluating whether a combination of radiation, chemotherapy, and immunotherapy is safe and effective for people with lung cancer.

See full description

Eligible Conditions

  • Adenocarcinoma of Lung
  • Lung Cancer
  • Adenocarcinoma
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • Lung Neoplasms

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Treatment will improve 1 primary outcome and 3 secondary outcomes in patients with Adenocarcinoma of Lung. Measurement will happen over the course of Every 3 months for 2 years.

2 years
Overall Survival
Post-treatment Pulmonary Function
Treatment Morbidity and Mortality
Year 2
Progressive free survival

Trial Safety

Safety Estimate

1 of 3

Trial Design

1 Treatment Groups

Control

This trial requires 100 total participants across 1 different treatment groups

This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 2 years for reporting.

Who is running the study

Principal Investigator
D. W.
Dennis Wigle, PhD
Mayo Clinic

Closest Location

Mayo Clinic in Rochester - Rochester, MN

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Two or more GGO's or solid lesions suspicious for multifocal disease.
Clinical diagnosis of N0
PFT's that show patient is capable of tolerating a lung resection.
Patient must be able to understand and willing to sign an IRB-approved informed consent document
Patient must be > 18 years of age
No evidence of distant metastases
No prior intra-thoracic radiation therapy (NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted.), previous chemotherapy, or surgical resection for non-small cell lung cancer (NSCLC).
No other cancer in the past 5 years except early stage prostate cancer, or basal cell of skin.
Non-pregnant and non-lactating. Women of child-bearing potential must have a negative urine or serum pregnancy test to participate in the study.

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is adenocarcinoma of lung?

Add answer

Adenocarcinoma of the lung can originate from any of the various epithelial tissues in the lung. Adenocarcinoma of the lung is the tumor of most malignant potential. Most lung adenocarcinomas form in the lung tissue and metastasizes with time. There is a tendency for tumors to grow larger over time before metastasis. This is due to the tendency for carcinoma of the lung tissue to spread as it multiplies and grows in size. Adenocarcinoma of the lung accounts for the majority of lung cancer deaths. Adenocarcinoma in the lung has been shown to have the strongest effect on survival in cases of curative resection.

Unverified Answer

What are the signs of adenocarcinoma of lung?

Add answer

Coughing up blood, coughing up blood with a weight loss ≥10% is one of the most common signs of adenocarcinoma of the lung. The duration of smoking,

Unverified Answer

What are common treatments for adenocarcinoma of lung?

Add answer

Recent findings highlighted several key points for the treatment of patients with lung adenocarcinoma. First, the treatment regime should be tailored to the clinical presentation, and consideration to exclude metastasis should be made. Second, lung adenocarcinoma can be cured by radical surgery, and adjuvant chemotherapy and radiotherapy offer some prolongation of survival.

Unverified Answer

Can adenocarcinoma of lung be cured?

Add answer

Adenocarcinoma of lung does not seem to be one of the curable tumors under the best of present medical treatment. The cure rate is quite low for many tumors, including those with poor or no histologic differentiation. It will be important to define the subtype of adenocarcinoma of lung, using molecular markers, to predict the prognosis from a new perspective. We speculate that we need to improve our current treatment modalities for this subtype of lung cancer in the early stage so that more patients may have a better chance for cure.

Unverified Answer

How many people get adenocarcinoma of lung a year in the United States?

Add answer

Findings from a recent study suggests that there are approximately 250,000 new cases of lung cancer every year in the United States, with incidence in the majority of patients with adenocarcinoma (85%) as opposed to squamous cell (4.3% and 3.8% for adenocarcinoma and squamous cell, respectively).

Unverified Answer

What causes adenocarcinoma of lung?

Add answer

Results from a recent paper suggests that lung cancers in people with smoking habits may be caused by the carcinogens of cigarette smoking. The data indicate that smoking is associated with increased risk of lung adenocarcinoma.

Unverified Answer

Is treatment typically used in combination with any other treatments?

Add answer

Patients undergoing treatment of lung adenocarcinoma were typically treated in combination with surgical therapy in addition to radiotherapy and/or adjuvant agents, but most were treated in combination with systemic therapy, including chemotherapy. Use of non-systemic approaches was generally restricted to early-stage non-small-cell carcinoma patients, whereas systemic chemotherapy was used more often in patients with unresectable tumors. Clinicians are encouraged to consider using multimodal therapies in treating patients with lung adenocarcinoma because of the positive impact on local, regional, and distant recurrence, and survival.

Unverified Answer

How serious can adenocarcinoma of lung be?

Add answer

Adenocarcinomas of the lung are highly lethal when diagnosed in the early stages. Lung Adenocarcinoma patients who have a higher percentage of tumour in the lower lobes, who reach a stage sooner after diagnosis, and who have more aggressive tumour types have a particularly high fatality rate. Further improvements in adjuvant chemotherapy and staging protocols are warranted in these high-risk patients.

Unverified Answer

Has treatment proven to be more effective than a placebo?

Add answer

Given the fact that we have no evidence of any treatment having better efficacy, the current practice of utilizing conventional chemotherapy as a first-line treatment option for most patients with advanced NSCLC may be inappropriate. Further research should be conducted to determine the most effective treatment method for such patients.

Unverified Answer

What is the latest research for adenocarcinoma of lung?

Add answer

The current management for adenocarcinoma of lung comprises chemotherapy in combination with adjuvant radiation in adjuvant therapy for lymph node-positive disease and pN2+ primary tumor, as well as adjuvant radiation with concurrent chemotherapy for patients with pN2+ non-SLN metastasis and non-SLN involvement. As new treatments are developed, surgical resection in combination with post-operative chemotherapy should be considered for patients with resectable non-SLN involvement, pN2 disease, and non-SLN metastasis.

Unverified Answer

What is the average age someone gets adenocarcinoma of lung?

Add answer

Nearly half of people diagnosed with adenocarcinoma of lung were not younger than age 75 years. There were no differences in age distribution for gender, race, ethnicity and marital status.

Unverified Answer

What are the latest developments in treatment for therapeutic use?

Add answer

There is limited evidence of benefit of neoadjuvant therapy for Stage III non-small cell lung cancer. More work is needed to investigate this approach in order to improve its effectiveness. In a small pilot study, the use of pemetrexed in combination with cisplatin provided acceptable toxicity and disease control, which warrants further trial.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Adenocarcinoma of Lung by sharing your contact details with the study coordinator.